Sharon Benzeno Sells 154,768 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Sharon Benzeno sold 154,768 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $3,271,795.52. Following the completion of the transaction, the insider owned 221,278 shares of the company’s stock, valued at $4,677,816.92. This represents a 41.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sharon Benzeno also recently made the following trade(s):

• On Friday, June 26th, Sharon Benzeno sold 11,034 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $21.00, for a total value of $231,714.00.

Adaptive Biotechnologies Stock Performance

Shares of NASDAQ:ADPT opened at $22.37 on Thursday. The firm has a market cap of $3.58 billion, a price-to-earnings ratio of -67.79 and a beta of 2.07. The business has a 50-day simple moving average of $15.81 and a two-hundred day simple moving average of $15.79. Adaptive Biotechnologies Corporation has a fifty-two week low of $9.96 and a fifty-two week high of $22.54.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same quarter last year, the firm posted ($0.20) EPS. The business’s quarterly revenue was up 35.1% compared to the same quarter last year. As a group, research analysts predict that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on ADPT. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. TD Cowen increased their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. BTIG Research restated a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday, June 17th. Morgan Stanley cut their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Finally, JPMorgan Chase & Co. reduced their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and an average price target of $20.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Westfield Capital Management Co. LP bought a new stake in shares of Adaptive Biotechnologies during the 4th quarter valued at $65,942,000. Price T Rowe Associates Inc. MD increased its stake in shares of Adaptive Biotechnologies by 303.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after purchasing an additional 3,299,635 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after purchasing an additional 2,731,648 shares during the period. Invesco Ltd. raised its holdings in Adaptive Biotechnologies by 248.8% in the 4th quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after purchasing an additional 2,216,595 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after purchasing an additional 2,062,282 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.